AR041271A1 - Quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa - Google Patents
Quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasaInfo
- Publication number
- AR041271A1 AR041271A1 ARP030103355A AR041271A1 AR 041271 A1 AR041271 A1 AR 041271A1 AR P030103355 A ARP030103355 A AR P030103355A AR 041271 A1 AR041271 A1 AR 041271A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- nr4r5
- groups
- nr7r8
- substituted
- Prior art date
Links
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 title 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 13
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000004429 atom Chemical group 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 2
- 229910006069 SO3H Inorganic materials 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 2
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 abstract 1
- -1 SO2CH3 Chemical group 0.000 abstract 1
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
Abstract
Quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa, a su uso como medicamento, a composiciones farmacéuticas que los contienen y a un procedimiento para su preparación. Reivindicación 1: Un compuesto de la fórmula (1)caracterizado porque, m es 1, 2, o 3, y R1 se selecciona entre CH3, Cl, Br, y F, y R2 se selecciona de: Q1-Q2-Q3-Q4 en la que: Q1 es un enlace sencillo o un grupo alquileno C1-6 lineal o ramificado; Q2 es un heterociclo saturado de 4 a 6 miembrosque comprende uno o dos heteroátomos seleccionados entre O o N; Q3 es un grupo alquileno C1-6 lineal o ramificado; Q4 es un heterociclo de 4 a 8 miembros, aromático o no aromático, que comprende de 1 a 4 heteroátomos seleccionados entre O, S, S(=O),SO2 y N, dicho heterociclo está opcionalmente sustituido con uno o varios grupos seleccionados entre OR, NRR´, CN y alquilo C1-6, en los que R y R´ son iguales o diferentes y se seleccionan entre H y alquilo C1-6; el átomo de Q2 unido a Q1 es unátomo de C, y, el átomo de Q4 unido a Q3 es un átomo de C; alquilo C1-6, dicho grupo alquilo está sustituido con 1 a 3 grupos, preferiblemente 1, seleccionado entre OR4, COOR4, NR4R5, NRC(=O)R4, C(=O)NR4R5 y SO2NR4R5, en los que, R es H o alquilo C1-6; R4 es alquilo C1-6 sustituido con uno o varios grupos, preferiblemente de 1 a 3, seleccionados entre F, CN, S(=O)R6, SO3H, SO2R6, SR7, C(=O)-NH-SO2-CH3, -C(=O)R7, NR´C(=O)R7, NR´SO2R6, C(=O)NR7R8, O-C(=O)NR7R8 y SO2NR7R8, en los que R´ es H, oalquilo C1-6, R6 es alquilo C1-6 opcionalmente sustituido con uno o dos grupos OR" en los que R" se selecciona entre H y alquilo C1-6, y R7 y R8 son iguales o diferentes y se seleccionan entre H y R6. R5 se selecciona entre R4, H y alquilo C1-6; odicho grupo alquilo está 1) sustituido con de 1 a 3 grupos, preferiblemente 1, seleccionado entre OC(=O)R4, SR4, S(=O)R3, C(=NR9)R4, C(=NR9)-NR4R5, NR-C(=NR9)-NR4R5, NRCOOR4, NR-C(=O)-NR4R5, NR-SO2-NR4R5, NR-C(=NR9)-R4 y NR-SO2-R3 y, 2)opcionalmente sustituido con 1 o 2 grupos seleccionados entre OR4, COOR4, C(=O)-R4, NR4R5, NRC(=O)R4, C(=O)NR4R5 y SO2NR4R5; en los que, R se selecciona entre H y alquilo C1-6; R9 se selecciona entre H, CN, OH, OCH3, SO2CH3, SO2NH2 y alquilo C1-6, yR3 es alquilo C1-6, sustituido o insustituido con uno o varios grupos, preferiblemente de 1 a 3, seleccionados entre F, CN, S(=O)R6, SO3H, SO2R6, C(=O)-NH-SO2-CH3, OR7, SR7, COOR7, C(=O)R7, O-C(=O)NR7R8, NR7R8, NR´C(=O)R7, NR´SO2R6, C(=O)NR7R8 ySO2NR7R8, en los que R´ es H o alquilo C1-6; R6 es alquilo C1-6 opcionalmente sustituido con uno o dos grupos OR", en los que R" se selecciona entre H y alquilo C1-6 y R7 y R8 son iguales o diferentes y se seleccionan entre H y R6; R4 y R5 soniguales o diferentes y se seleccionan entre H y R3; o sus formas racémicas, sus isómeros y sus derivados farmacéuticamente aceptables
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20020292275 EP1400244A1 (en) | 2002-09-17 | 2002-09-17 | New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR041271A1 true AR041271A1 (es) | 2005-05-11 |
Family
ID=31896987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030103355 AR041271A1 (es) | 2002-09-17 | 2003-09-16 | Quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7429598B2 (es) |
| EP (2) | EP1400244A1 (es) |
| JP (1) | JP2006501277A (es) |
| KR (1) | KR20050057371A (es) |
| CN (1) | CN1681507A (es) |
| AP (1) | AP2005003251A0 (es) |
| AR (1) | AR041271A1 (es) |
| AU (1) | AU2003259496A1 (es) |
| BR (1) | BR0314379A (es) |
| CA (1) | CA2499330C (es) |
| CO (1) | CO5540391A2 (es) |
| CR (1) | CR7728A (es) |
| EA (1) | EA200500312A1 (es) |
| EC (1) | ECSP055671A (es) |
| GT (1) | GT200300201A (es) |
| HN (1) | HN2003000285A (es) |
| HR (1) | HRP20050223A2 (es) |
| IS (1) | IS7700A (es) |
| MA (1) | MA27439A1 (es) |
| MX (1) | MXPA05002913A (es) |
| NO (1) | NO20051695L (es) |
| OA (1) | OA12924A (es) |
| PA (1) | PA8582801A1 (es) |
| PE (1) | PE20050073A1 (es) |
| PL (1) | PL375977A1 (es) |
| TN (1) | TNSN05073A1 (es) |
| TW (1) | TWI251590B (es) |
| UY (1) | UY27986A1 (es) |
| WO (1) | WO2004026818A1 (es) |
| ZA (1) | ZA200501381B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2425013T3 (es) | 2002-06-12 | 2013-10-10 | Symphony Evolution, Inc. | Inhibidores de ADAM-10 humana |
| GB0504209D0 (en) * | 2005-03-01 | 2005-04-06 | Pfizer Ltd | New use of PDE7 inhibitors |
| BRPI0607402A2 (pt) * | 2005-03-01 | 2009-09-01 | Pfizer Ltd | uso de inibidores de pde7 para o tratamento de dor neuropática |
| WO2006092692A1 (en) * | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain |
| WO2007025177A2 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| JP2009512711A (ja) | 2005-10-21 | 2009-03-26 | ブレインセルス，インコーポレイティド | Ｐｄｅ阻害による神経新生の調節 |
| CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| KR101009554B1 (ko) | 2005-12-02 | 2011-01-18 | 화이자 리미티드 | Ｐｄｅ７ 억제제로서 스피로시클릭 퀴나졸린 유도체 |
| NZ570014A (en) | 2006-02-03 | 2011-04-29 | Bionomics Ltd | Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
| EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| AU2007292848A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| CN101917992A (zh) | 2007-03-27 | 2010-12-15 | 奥默罗斯公司 | 用于治疗运动障碍的pde7抑制剂的用途 |
| US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
| US20100216823A1 (en) * | 2007-05-24 | 2010-08-26 | Pfizer Inc. | Spirocyclic Derivatives |
| US7968536B2 (en) * | 2007-06-29 | 2011-06-28 | Millennium Pharmaceuticals, Inc. | Heterocyclic compounds useful as RAF kinase inhibitors |
| CL2008001933A1 (es) | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
| PT2326650E (pt) | 2008-08-06 | 2014-05-06 | Biomarin Pharm Inc | Inibidores de di-hidropiridoftalazinona de poli(adpribose) polimerase (parp) |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| AU2011212928B2 (en) | 2010-02-03 | 2016-06-23 | Medivation Technologies Llc | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose) polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency |
| US20110190266A1 (en) * | 2010-02-04 | 2011-08-04 | Daniel Chu | 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) |
| HUE030794T2 (en) * | 2010-02-08 | 2017-06-28 | Medivation Technologies Inc | Synthesis Processes of Dihydro-Pyrido-Phthalazinone Derivatives |
| RU2598606C3 (ru) | 2010-10-21 | 2021-12-20 | МЕДИВЭЙШН ТЕКНОЛОДЖИЗ ЭлЭлСи | Кристаллическая тозилатная соль (8s,9r)-5-фтор-8-(4-фторфенил)-9-(1-метил-1н-1,2,4-триазол-5-ил)-8-9-дигидро-2н-пиридо[4,3,2-de]фталазин-3(7н)-она |
| US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
| CN103547267A (zh) | 2010-11-08 | 2014-01-29 | 奥默罗斯公司 | 使用pde7抑制剂治疗成瘾和冲动控制障碍 |
| US20150119399A1 (en) | 2012-01-10 | 2015-04-30 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| CA3069432A1 (en) | 2017-07-12 | 2019-01-17 | Dart Neuroscience, Llc | Substituted benzoxazole and benzofuran compounds as pde7 inhibitors |
| CN112574202B (zh) * | 2020-12-11 | 2021-11-09 | 台州学院 | 一种螺喹唑啉-2-酮类衍生物及其制备方法和应用 |
| WO2024038090A1 (en) | 2022-08-18 | 2024-02-22 | Mitodicure Gmbh | Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5959685A (ja) * | 1982-09-28 | 1984-04-05 | Kyowa Hakko Kogyo Co Ltd | 新規なピペリジン誘導体 |
| JPS5959865A (ja) * | 1982-09-30 | 1984-04-05 | Ube Ind Ltd | 耐熱鋳鋼 |
| US4666913A (en) * | 1985-11-22 | 1987-05-19 | William H. Rorer, Inc. | Hydroxy and aminothiazolyl-benzodiazinone compounds, cardiotonic compositions including the same, and their uses |
| US4906630A (en) * | 1985-11-22 | 1990-03-06 | Rorer Pharmaceutical Corporation | Method of increasing cardiac contractility using pharmaceutical compositions comprising benzodiazinone- pyridazinone or hydroxy-pyrazolyl compounds |
| US4764512A (en) | 1986-08-27 | 1988-08-16 | Rorer Pharmaceutical Corporation | Benzodiazinone-pyridone compounds, cardiotonic compositions including the same, and their uses |
| US5102886A (en) | 1990-10-12 | 1992-04-07 | American Home Products Corporation | 1'-aminospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrones and analogs thereof useful as aldose reductase inhibitors |
| IL102764A0 (en) * | 1991-08-16 | 1993-01-31 | Merck & Co Inc | Quinazoline derivatives,and pharmaceutical compositions containing them |
| WO2000066560A1 (en) | 1999-05-04 | 2000-11-09 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| WO2002076953A1 (en) * | 2001-03-21 | 2002-10-03 | Warner-Lambert Company Llc | New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors |
| US6596167B2 (en) | 2001-03-26 | 2003-07-22 | Koch Membrane Systems, Inc. | Hydrophilic hollow fiber ultrafiltration membranes that include a hydrophobic polymer and a method of making these membranes |
-
2002
- 2002-09-17 EP EP20020292275 patent/EP1400244A1/en not_active Withdrawn
-
2003
- 2003-09-08 OA OA1200500073A patent/OA12924A/en unknown
- 2003-09-08 CN CNA038221284A patent/CN1681507A/zh active Pending
- 2003-09-08 PL PL37597703A patent/PL375977A1/xx not_active Application Discontinuation
- 2003-09-08 EP EP20030797455 patent/EP1542694A1/en not_active Withdrawn
- 2003-09-08 EA EA200500312A patent/EA200500312A1/ru unknown
- 2003-09-08 CA CA 2499330 patent/CA2499330C/en not_active Expired - Fee Related
- 2003-09-08 JP JP2004537412A patent/JP2006501277A/ja not_active Withdrawn
- 2003-09-08 BR BR0314379A patent/BR0314379A/pt not_active IP Right Cessation
- 2003-09-08 AU AU2003259496A patent/AU2003259496A1/en not_active Abandoned
- 2003-09-08 MX MXPA05002913A patent/MXPA05002913A/es active IP Right Grant
- 2003-09-08 AP AP2005003251A patent/AP2005003251A0/xx unknown
- 2003-09-08 KR KR1020057004511A patent/KR20050057371A/ko not_active Application Discontinuation
- 2003-09-08 WO PCT/IB2003/003965 patent/WO2004026818A1/en active Application Filing
- 2003-09-16 AR ARP030103355 patent/AR041271A1/es unknown
- 2003-09-16 TW TW92125477A patent/TWI251590B/zh not_active IP Right Cessation
- 2003-09-16 PA PA8582801A patent/PA8582801A1/es unknown
- 2003-09-16 PE PE2003000943A patent/PE20050073A1/es not_active Application Discontinuation
- 2003-09-17 UY UY27986A patent/UY27986A1/es not_active Application Discontinuation
- 2003-09-17 US US10/667,111 patent/US7429598B2/en not_active Expired - Fee Related
- 2003-09-17 HN HN2003000285A patent/HN2003000285A/es unknown
- 2003-09-17 GT GT200300201A patent/GT200300201A/es unknown
-
2005
- 2005-02-16 ZA ZA200501381A patent/ZA200501381B/xx unknown
- 2005-02-17 IS IS7700A patent/IS7700A/is unknown
- 2005-03-08 HR HR20050223A patent/HRP20050223A2/hr not_active Application Discontinuation
- 2005-03-10 CR CR7728A patent/CR7728A/es not_active Application Discontinuation
- 2005-03-11 EC ECSP055671 patent/ECSP055671A/es unknown
- 2005-03-16 CO CO05024530A patent/CO5540391A2/es not_active Application Discontinuation
- 2005-03-17 MA MA28153A patent/MA27439A1/fr unknown
- 2005-03-17 TN TNP2005000073A patent/TNSN05073A1/fr unknown
- 2005-04-05 NO NO20051695A patent/NO20051695L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003259496A1 (en) | 2004-04-08 |
| TWI251590B (en) | 2006-03-21 |
| TW200413333A (en) | 2004-08-01 |
| NO20051695L (no) | 2005-04-05 |
| EA200500312A1 (ru) | 2005-08-25 |
| TNSN05073A1 (fr) | 2007-05-14 |
| MXPA05002913A (es) | 2005-05-27 |
| CA2499330A1 (en) | 2004-04-01 |
| KR20050057371A (ko) | 2005-06-16 |
| CO5540391A2 (es) | 2005-07-29 |
| HRP20050223A2 (en) | 2005-10-31 |
| OA12924A (en) | 2006-10-13 |
| MA27439A1 (fr) | 2005-07-01 |
| PA8582801A1 (es) | 2004-05-26 |
| ZA200501381B (en) | 2006-11-29 |
| US7429598B2 (en) | 2008-09-30 |
| PL375977A1 (en) | 2005-12-12 |
| EP1400244A1 (en) | 2004-03-24 |
| PE20050073A1 (es) | 2005-02-28 |
| BR0314379A (pt) | 2005-07-19 |
| CN1681507A (zh) | 2005-10-12 |
| CA2499330C (en) | 2009-04-28 |
| GT200300201A (es) | 2004-05-18 |
| HN2003000285A (es) | 2004-11-23 |
| IS7700A (is) | 2005-02-17 |
| AP2005003251A0 (en) | 2005-03-31 |
| UY27986A1 (es) | 2004-04-30 |
| EP1542694A1 (en) | 2005-06-22 |
| CR7728A (es) | 2005-06-08 |
| JP2006501277A (ja) | 2006-01-12 |
| ECSP055671A (es) | 2005-05-30 |
| US20040106631A1 (en) | 2004-06-03 |
| WO2004026818A1 (en) | 2004-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR041271A1 (es) | Quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa | |
| AR008377A1 (es) | Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto | |
| AR034475A1 (es) | Derivados de androstano antiinflamatorios | |
| AR040474A1 (es) | Derivados de tiofenolglicosido, procedimientos para la preparacion de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos | |
| CO4900063A1 (es) | Piridinas substituidas como inhibidores selectivos de ciclo- oxi-genasa2 | |
| AR029766A1 (es) | Compuesto inhibidor de quinasa y uso del mismo para preparar una composicion farmaceutica | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| AR051735A1 (es) | Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos. | |
| AR029301A1 (es) | Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos | |
| DK389480A (da) | Derivater af 6beta-hydroxyalkyl-penicillansyrer til anvendelse som beta-lactamse-inhibitorer | |
| ES2081187T3 (es) | Nuevas naftil-alquil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen. | |
| AR048213A1 (es) | 1-(4-mono-y di-halometilsulfonilfenil)-2-acilamino-fluorpropanoles analogos al florfenicol | |
| AR069435A1 (es) | Derivados de aminotiazol, proceso para la obtencion de los mismos, composiciones farmaceuticas y su uso como inhibidores de la fbpasa | |
| MX9303441A (es) | Procedimiento para la preparacion de acido clavulanico. | |
| MX9204622A (es) | Nuevos derivados de 3,5-di-tert-butil-4-hidroxifenilo, procedimiento para su preparacion y composicion farmaceutica que los contiene. | |
| ES2118203T3 (es) | Nuevos derivados benzopiranicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen. | |
| UY27338A1 (es) | Nuevos derivados de ácido sulfónico | |
| AR012622A1 (es) | Inhibidores de proteasas, procedimiento para su preparacion, composicion farmaceutica que los comprende y el uso de los mismos en la fabricacion de unmedicamento | |
| DK269083A (da) | Hydroxyalkynyl-azolyl-derivater, fremgangsmaade til deres fremstilling samt deres anvendelse som fungicider | |
| MX9304467A (es) | Nuevos derivados fosfonados de ariletanolaminas, procedimiento para su preparacion y composiciones farmaceuticas y veterinarias que los contienen. | |
| ES2095848T3 (es) | Nuevos derivados de fosfolipidos y su utilizacion para la preparacion de medicamentos antiviricos. | |
| ES2087729T3 (es) | Derivados de 2-amino-1,2,3,4-tetrahidronaftaleno activos sobre el sistema cardiovascular, procedimientos para su preparacion y composiciones farmaceuticas que los contienen. | |
| AR035601A1 (es) | Procesos de preparacion de inhibidores del intercambiador de sodio-hidrogeno de tipo 1, inhibidores, sales de dichos compuestos, composiciones farmaceuticas y uso de los mismos en la preparación de medicamentos | |
| AR018652A1 (es) | Inhibidor de catepsina k del tipo pirrolidinona, composicion farmaceuticamente eficaz, usos de dichos compuestos para preparar medicamentos, yprocedimiento para producir dichos inhibidores | |
| CO5290255A1 (es) | Pirazolo(4,3-e)diazepinas sustituidas novedosas, composiciones farmaceuticas que las contienen, su uso como productos medicinales y procesos para prepararlas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |